search button

Evaluation of the efficacy of steroid therapy on acute liver failure

  • Authors:
    • Bo Zhao
    • Hui‑Yan Zhang
    • Gui‑Juan Xie
    • Hui‑Min Liu
    • Qing Chen
    • Rui‑Feng Li
    • Jian‑Ping You
    • Sha Yang
    • Qing Mao
    • Xu‑Qing Zhang

  • View Affiliations

  • Published online on: September 20, 2016     https://doi.org/10.3892/etm.2016.3720
  • Pages: 3121-3129
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The effects of corticosteroids in the treatment of patients with acute or subacute liver failure (ALF or SALF) are controversial. The aims of the present study were to evaluate the efficacy of corticosteroids in improving spontaneous survival (SS) rate in patients with ALF and SALF, and to determine the groups with the highest rates of response to, and the most effective timing of, corticosteroid administration. A retrospective analysis was performed of all patients with ALF and SALF who were hospitalized in the Department of Infectious Diseases, Southwest Hospital, Chongqing, China from 2000‑2012. The most common result of this was SS. A total of 238 patients were studied, including 73 patients with ALF (n=34 steroids, n=39 no steroids) and 165 patients with SALF (n=21 steroids, n=144 no steroids). Corticosteroids improved rates of SS in patients with liver failure (steroids vs. no steroids, 38.2 vs. 20.2%; P=0.011), including patients with ALF (steroids vs. no steroids, 29.4 vs. 5.1%; P=0.013) and with SALF (steroids vs. no steroids, 52.4 vs. 24.3%; P=0.013), patients with viruses (steroids vs. no steroids, 32.4 vs. 14.1%; P=0.042) and patients without viruses (steroids vs. no steroids, 50.0 vs. 24.1%; P=0.043). SS rates were extremely low for patients with coma grade 4 or Model for End‑stage Liver Disease (MELD) scores ≥35 (2.2 vs. 11.8%; P=0.180). A significantly improved rate of SS associated with steroid use was observed among patients who had alanine aminotransferase (ALT) levels ≥30 x the upper limit of normal and coma grade <4 and MELD scores <35 (65.0 vs. 17.4%; P=0.002). SS associated with steroid use was significantly higher in patients with an illness duration ≤2 weeks compared with patients with an illness duration >2 weeks (51.4 vs. 15.0%; P=0.010). Corticosteroids improved the prognosis of patients with ALF and SALF. The highest rates of response were observed in patients with a lower MELD score and coma grade but who had extremely high ALT levels. The most effective treatment time was within 2 weeks of the onset of symptoms.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao B, Zhang HY, Xie GJ, Liu HM, Chen Q, Li RF, You JP, Yang S, Mao Q, Zhang XQ, Zhang XQ, et al: Evaluation of the efficacy of steroid therapy on acute liver failure. Exp Ther Med 12: 3121-3129, 2016.
APA
Zhao, B., Zhang, H., Xie, G., Liu, H., Chen, Q., Li, R. ... Zhang, X. (2016). Evaluation of the efficacy of steroid therapy on acute liver failure. Experimental and Therapeutic Medicine, 12, 3121-3129. https://doi.org/10.3892/etm.2016.3720
MLA
Zhao, B., Zhang, H., Xie, G., Liu, H., Chen, Q., Li, R., You, J., Yang, S., Mao, Q., Zhang, X."Evaluation of the efficacy of steroid therapy on acute liver failure". Experimental and Therapeutic Medicine 12.5 (2016): 3121-3129.
Chicago
Zhao, B., Zhang, H., Xie, G., Liu, H., Chen, Q., Li, R., You, J., Yang, S., Mao, Q., Zhang, X."Evaluation of the efficacy of steroid therapy on acute liver failure". Experimental and Therapeutic Medicine 12, no. 5 (2016): 3121-3129. https://doi.org/10.3892/etm.2016.3720